April 16, Weixinkang(603676) issued an announcement that its wholly-owned subsidiary Baiyi Pharmaceutical recently received the "Drug Clinical Trial Approval Notice" for Succinylated Gelatin Electrolyte Sodium Acetate Injection approved and issued by the National Medical Products Administration.

The drug is an injection with a specification of 500 mg, and the application is for clinical trials. The approval conclusion shows that the clinical trial application for succinylated gelatin electrolyte sodium acetate injection meets the relevant requirements for drug registration and is approved for clinical trials.

As of March 2025, the company's cumulative R&D investment in this drug is approximately RMB 3.15 million. As a colloidal plasma volume substitute, succinylated gelatin electrolyte sodium acetate injection is mainly used for the treatment of hypovolemia and shock, and can be used in combination with crystalloid solutions. The announcement also mentioned that B. Braun Medical's similar drug has been approved for marketing, and five other companies have also obtained approval for clinical trials of the drug.

In the first three quarters of 2024, Weixinkang achieved revenue of 994 million yuan and net profit attributable to shareholders of the parent company of 243 million yuan.

https://finance.eastmoney.com/a/202504163378647271.html